Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer (Q24202199)

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

TRIO-012: a multicenter, multinational, randomized, double-blind phase III study of IMC-1121B plus docetaxel versus placebo plus docetaxel in previously untreated patients with HER2-negative, unresectable, locally recurrent or metastatic breast canc

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Angiogenesis and lymphangiogenesis are downregulated in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Detecting an overall survival benefit that is derived from progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Directed therapy of subtypes of triple-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Evaluating non-randomised intervention studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

VEGF-targeted therapy: mechanisms of anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Triple-negative breast cancer: an unmet medical need

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Advanced methods in meta-analysis: multivariate approach and meta-regression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Benefits and harms of drug treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

What is the best evidence for determining harms of medical treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Anti-angiogenic therapies for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

7 January 2021

Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

7 January 2021

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

7 January 2021

Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

7 January 2021

Practical methods for incorporating summary time-to-event data into meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

7 January 2021

Phase II evaluation of thalidomide in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

7 January 2021

Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

7 January 2021

RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic br

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008941.PUB2

7 January 2021

10.1002/14651858.CD008941.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

4940370

OpenCitations bibliographic resource ID

4940370

1 reference